Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Patients with kidney failure have underlying bone disease at the time of transplant.
Fractures of various bones can be as high as 22%. Medication required for the transplant
plays a role in bone loss.
Bisphosphonates are used in the general population to treat bone loss of osteoporosis and
steroid-induced bone loss. While previous studies, using various bisphosphonates, have shown
preservation of bone mineral density in renal transplant recipients, we have demonstrated
that pamidronate, a second generation bisphosphonate, is associated with low bone turnover
while still preserving bone mineral density. Improved bone mineral density is associated with
decreased fracture risk in the general population, while low bone turnover may be associated
with increased fracture in dialysis patients.
The purpose of this study is to determine whether risedronate, a third generation
bisphosphonate, is effective in preserving bone density when given prophylactically following
renal transplantation and whether it is associated with low bone turnover at one year
following renal transplantation.